BioCryst Pharmaceuticals’ (BCRX) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued to investors on Friday,Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price objective on the stock. Evercore ISI lifted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Stock Up 6.4 %

BCRX stock opened at $6.82 on Friday. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -11.18 and a beta of 1.75. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $9.50. The business has a 50 day moving average price of $7.96 and a two-hundred day moving average price of $7.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period in the previous year, the company earned $0.28 earnings per share. The company’s quarterly revenue was up 40.8% compared to the same quarter last year. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Captrust Financial Advisors grew its stake in shares of BioCryst Pharmaceuticals by 19.4% in the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,644 shares in the last quarter. Quantinno Capital Management LP acquired a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $82,000. Wellington Management Group LLP bought a new position in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $819,000. Geode Capital Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after buying an additional 127,708 shares during the period. Finally, SkyView Investment Advisors LLC increased its stake in BioCryst Pharmaceuticals by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 3,000 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.